2025
16 Metabolic Syndrome and Obesity
Alonso W, Canapari C. 16 Metabolic Syndrome and Obesity. 2025, 175-184. DOI: 10.1016/b978-0-323-75566-5.00016-2.Peer-Reviewed Original ResearchMetabolic syndromeComponents of metabolic syndromeInvolvement of adipocytokinesSleep-disordered breathingIncreased sympathetic activityElevated blood pressureCardiovascular risk factorsRates of obesityIntermittent hypoxemiaTruncal obesityDysregulation of glucose metabolismSleep fragmentationSympathetic activityBlood pressureSleep curtailmentRisk factorsSyndromeObesityShort sleepGlucose metabolismCircadian factorsSleepHypoxemiaDyslipidemiaAdipocytokines
2022
Biallelic BICD2 variant is a novel candidate for Cohen-like syndrome
Caglayan AO, Tuysuz B, Gül E, Alkaya DU, Yalcinkaya C, Gleeson JG, Bilguvar K, Gunel M. Biallelic BICD2 variant is a novel candidate for Cohen-like syndrome. Journal Of Human Genetics 2022, 67: 553-556. PMID: 35338243, PMCID: PMC9420744, DOI: 10.1038/s10038-022-01032-1.Peer-Reviewed Original ResearchConceptsWhole-exome sequencing analysisTruncal obesityJoint hypermobilityLower extremitiesHomozygous missense mutationSevere formBICD2 mutationsType 2BHeterozygous mutationsSpeech delayType 2AIntellectual disabilityPatientsSyndromeConsanguineous unionsMissense mutationsNovel candidatesSequencing analysisFirst reportMutations
2018
Endometrial Carcinoma in a 26‐Year‐Old Patient with Bardet‐Biedl Syndrome
Grechukhina O, Gressel GM, Munday W, Wong S, Santin A, Vash-Margita A. Endometrial Carcinoma in a 26‐Year‐Old Patient with Bardet‐Biedl Syndrome. Case Reports In Obstetrics And Gynecology 2018, 2018: 1952351. PMID: 29854508, PMCID: PMC5960523, DOI: 10.1155/2018/1952351.Peer-Reviewed Original ResearchAbnormal uterine bleedingBardet-Biedl syndromeEndometrial cancerUterine bleedingRisk factorsDefinitive surgical treatmentIndependent risk factorEndometrioid endometrial adenocarcinomaRare genetic conditionOvulatory dysfunctionBilateral salpingectomyCentral obesityOlder patientsTruncal obesityYounger patientsEndometrioid adenocarcinomaSurgical treatmentEndometrial adenocarcinomaEndometrial carcinomaClinical signsCognitive impairmentPatientsCancerGenetic conditionsBleeding
2015
New targets to treat obesity and the metabolic syndrome
Martin KA, Mani MV, Mani A. New targets to treat obesity and the metabolic syndrome. European Journal Of Pharmacology 2015, 763: 64-74. PMID: 26001373, PMCID: PMC4573317, DOI: 10.1016/j.ejphar.2015.03.093.Peer-Reviewed Original ResearchConceptsMetabolic syndromeCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsPancreatic lipase inhibitor orlistatSingle CVD risk factorPeptide-1 receptor agonistsCVD risk factorsEpidemic of obesityLong-term treatmentType 2 diabetesLipase inhibitor orlistatDipeptidyl peptidase IV inhibitorsAnti-diabetic drugsFuture drug developmentTruncal obesitySerotonergic drugsReceptor agonistRisk factorsMelanocortin systemObesityMetabolic traitsSyndromeMetabolic profileIV inhibitorsNew targetsChitinase 3–like-1 Regulates Both Visceral Fat Accumulation and Asthma-like Th2 Inflammation
Ahangari F, Sood A, Ma B, Takyar S, Schuyler M, Qualls C, Dela Cruz CS, Chupp GL, Lee CG, Elias JA. Chitinase 3–like-1 Regulates Both Visceral Fat Accumulation and Asthma-like Th2 Inflammation. American Journal Of Respiratory And Critical Care Medicine 2015, 191: 746-757. PMID: 25629580, PMCID: PMC4407482, DOI: 10.1164/rccm.201405-0796oc.Peer-Reviewed Original ResearchConceptsHigh-fat dietTh2 inflammationTh2 responsesFat accumulationChitinase 3Genesis of obesityRole of CHI3L1Lower lung functionLean control subjectsVisceral fat accumulationPathogenesis of asthmaWhite adipose tissue accumulationAdipose tissue accumulationCase-control studySerum CHI3L1Truncal adiposityWAT accumulationPersistent asthmaTruncal obesityLung functionObese subjectsVisceral fatAsthma incidenceControl subjectsRisk factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply